



## Imugene Secures Important Intellectual Property Associated with Biolife Science Acquisition

---

### Highlights

- **Pevion Biotech assigns full rights to patent covering the manufacture of Her-Vaxx**
- **Important patent claims immunotherapy of commercial interest**
- **Her-Vaxx now patented in major markets until 2030**
- **Additional exclusive global license in the field of oncology for patent covering virosome vaccine delivery platform**

**Melbourne, 19 December 2013:** Australian drug development and pharmaceutical company Imugene (ASX:IMU) has announced today the acquisition of rights to two important pieces of intellectual property. Acquisition of this intellectual property is part the acquisition of Biolife Science Qld Limited (Biolife), which is set to close on the 20<sup>th</sup> December 2013.

Biolife has acquired the rights to a novel cancer immunotherapy platform that has been developed by scientists at the University Medical School in Austria. The immunotherapy induces an antibody response against HER-2/neu associated tumours, including breast cancer and gastric cancer ("Her-Vaxx"), which has been initially validated in clinical trials.

Global rights to two important and critical patents have been secured covering the "Her-Vaxx" immunotherapy being prepared for an FDA Phase II clinical trial, further protecting the immunotherapy of commercial interest to Biolife.

The first patent entitled "Multiepitope vaccine for her2/neu-associated cancers" has been assigned to Biolife from Pevion Biotech (Switzerland), protecting "Her-Vaxx" in major markets until 2030.

Biolife has additionally been granted an exclusive global license from Pevion Biotech in the field of oncology for a patent covering the virosome vaccine delivery platform, used in the manufacture of "Her-Vaxx". The patent entitled "Lyophilisation of Virosomes" confers on Biolife the right to practice the invention in all oncology fields and adds significant value to the transaction closing on the 20<sup>th</sup> December 2013.

Dr Nick Ede, Imugene Executive Director said, "Formalising the assignment and license of these important patents on very favourable terms is an important milestone delivered before the Biolife transaction concludes."

**-ends**

### Contact :

Dr Nick Ede, Imugene on 0400 642 254 or [nede@imugene.com](mailto:nede@imugene.com)

### Media contact:

Dr Douglas Pretsell, College Hill – +61 3 9657 0706 / [douglas.pretsell@collegehill.com](mailto:douglas.pretsell@collegehill.com)